Paid Clinical Trials in Pembroke Pines, FL

As of June 2026, 88 paid clinical trials are recruiting in Pembroke Pines, Florida. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 26, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

88 clinical trials

↓ Download CSV

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

for COVID-19 SARS-CoV-2 Infection

85 locations incl. Little Rock

Sponsor: Pfizer

Sex: All·Age: 12+

Code: NCT06679140·Phase 3·Recruiting

Apply to this trial

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

for Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

125 locations incl. Peoria

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632457·Phase 3·Recruiting

Apply to this trial

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

for Asthma

Drug: Lunsekimig

54 locations incl. Saraland

Sponsor: Sanofi

Sex: All·Age: 18 - 80

Code: NCT06676319·Phase 2·Recruiting

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

Drug: Mosunetuzumab

267 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting

Apply to this trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

for Non-small Cell Lung Cancer

Drug: Relatlimab

50 locations incl. Mobile

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06561386·Phase 3·Recruiting

Apply to this trial

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

for Asthma

Drug: Lunsekimig

29 locations incl. Chandler

Sponsor: Sanofi

Sex: All·Age: 18+

Code: NCT06609239·Phase 2·Enrolling By Invitation

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

165 locations incl. Birmingham

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

for NASH - Nonalcoholic Steatohepatitis

Drug: Efruxifermin

168 locations incl. Birmingham

Sponsor: Akero Therapeutics, Inc

Sex: All·Age: 18 - 80

Code: NCT06528314·Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

for Asthma

105 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 12 - 17

Code: NCT06307665·Phase 3·Recruiting

Apply to this trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Drug: Livmoniplimab

19 locations incl. La Jolla

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06236438·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

for COPD (Chronic Obstructive Pulmonary Disease)

235 locations incl. Athens

Sponsor: AstraZeneca

Sex: All·Age: 40 - 80

Code: NCT06283966·Phase 3·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

491 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

62 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting

Apply to this trial

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

for NASH With Fibrosis

Drug: Efruxifermin

205 locations incl. Birmingham

Sponsor: Akero Therapeutics, Inc

Sex: All·Age: 18 - 80

Code: NCT06215716·Phase 3·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

539 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting

Apply to this trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

148 locations incl. Dothan

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05952557·Phase 3·Recruiting

Apply to this trial

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

for Peripheral T Cell Lymphoma

11 locations incl. Clovis

Sponsor: Acrotech Biopharma Inc.

Sex: All·Age: 18+

Code: NCT06072131·Phase 3·Recruiting

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

186 locations incl. Alexander City

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting

Apply to this trial

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

for Primary Biliary Cholangitis (PBC)

Drug: Elafibranor

40 locations incl. Tucson

Sponsor: Ipsen

Sex: All·Age: 18+

Code: NCT06016842·Phase 3·Recruiting

Apply to this trial

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Nemtabrutinib

6 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05947851·Phase 3·Recruiting

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

476 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

323 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

785 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

184 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting

Apply to this trial

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

for Type2Diabetes

36 locations incl. Huntsville

Sponsor: Brigham and Women's Hospital

Sex: All·Age: 40 - 80

Code: NCT05390892·Phase 4·Recruiting

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

1021 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

for B-Cell Non-Hodgkin Lymphoma

25 locations incl. Clovis

Sponsor: ADC Therapeutics S.A.

Sex: All·Age: 18+

Code: NCT04970901·Phase 1·Recruiting

Apply to this trial

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

for Schizophrenia

Drug: KarXT

79 locations incl. Phoenix

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Sex: All·Age: 18 - 65

Code: NCT05304767·Phase 3·Recruiting

Apply to this trial

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

for Endometrial Cancer

24 locations incl. Phoenix

Sponsor: Mayo Clinic

Sex: Female·Age: 18+

Code: NCT05051722·Recruiting

Apply to this trial

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

for Pediatric Migraine

169 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT04649242·Phase 3·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1149 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

105 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

1229 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting

Apply to this trial